Ozempic, Wegovy, and Cancer scans: A Potential Diagnostic Issue

GLP-1 medications, Ozempic and Wegovy, may disrupt cancer imaging and its diagnosis, new research has revealed. GLP-1 agonists were first designed for type 2 Diabetes treatment, but over time, they grew popular for their non-approved use in weight loss.

GLP-1 (Glucagon-Like Peptide-1) is a hormone that helps lower blood sugar and control appetite by increasing insulin and slowing digestion.

The adverse effects of GLP-1 weight-loss medications have varied from mild to bizarre, ranging from deflated breasts and unexpected pregnancies to drooping jowls and sulphurous burps. Now, radiologists and imaging experts have identified a new issue: patients on these medications exhibit different uptake patterns on PET-CT scans.

According to recent research from imaging provider Alliance Medical, individuals on GLP-1 receptor agonists may exhibit abnormal FDG (fluorodeoxyglucose) uptake in PET-CT scans. FDG is a sugar used in PET scans to identify areas of high metabolic activity, frequently enough indicative of cancer. GLP-1 medications can alter how the body processes glucose, leading to false negatives or inaccurate interpretations of the scan results.

How GLP-1s interfere with PET-CT scans

PET-CT scans rely on detecting glucose metabolism.GLP-1 drugs affect glucose metabolism in several ways:

• Increased Insulin Sensitivity: GLP-1s enhance insulin sensitivity, causing cells to take up glucose more efficiently.
• Delayed Gastric Emptying: These medications slow down the rate at which food leaves the stomach, impacting glucose absorption.
• Pancreatic effects: GLP-1s stimulate insulin release from the pancreas, further influencing glucose levels.

These effects can result in lower FDG uptake in cancerous tissues, perhaps masking the presence of tumors or making them appear smaller than they are. Conversely, in some cases, altered glucose metabolism could lead to increased uptake in non-cancerous areas, creating false positives.

What This Means for Patients

If you are currently taking Ozempic, Wegovy, or another GLP-1 agonist and are scheduled for a PET-CT scan, it’s crucial to inform your doctor. The Alliance Medical research suggests temporarily discontinuing the medication before the scan may improve accuracy. However, do not stop taking your medication without consulting your physician. They will determine the best course of action based on your individual medical history and the reason for the scan.

Radiologists are becoming increasingly aware of this potential interference and are developing strategies to mitigate its effects. These strategies may include adjusting scan protocols or interpreting results with caution in patients on GLP-1 medications.

Key Takeaways

• GLP-1 medications like Ozempic and Wegovy can interfere with the accuracy of PET-CT scans.
• The medications alter glucose metabolism, potentially leading to false negatives or false positives.
• Patients on GLP-1s should inform their doctors before undergoing a PET-CT scan.
• Temporary discontinuation of the medication may be recommended, but only under medical supervision.
• Radiologists are adapting to address this issue and improve scan interpretation.

FAQ

Should I stop taking Ozempic/wegovy if I need a PET scan?

No, do not stop taking your medication without first consulting your doctor. They will assess your situation and provide personalized guidance.

How long before a PET scan should I stop taking GLP-1 medication?

The optimal duration for discontinuation is still being persistent. Your doctor will advise you based on your specific case.

Are other types of cancer scans affected by GLP-1 medications?

Currently, the primary concern is with PET-CT scans. More research is needed to determine if other imaging modalities are also affected.

What if I didn’t tell my doctor I was on Ozempic/Wegovy before my PET scan?

Inform your doctor promptly. They may recommend a follow-up scan or further investigation to ensure an accurate diagnosis.

Publication Date: 2025/10/08 10:18:34